Lifecore Biomedical Q3 2026 earnings

LFCR · 2026-11-04 07:13 BMO ET · 8-K on SEC · 10-Q on SEC

Revenue and gross profit declined year-over-year, while operating expenses fell sharply, narrowing the net loss.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$25.3M-19.0%-26.1%Ex. 99.1

Revenue breakdown

SegmentActualYoYShare of revenueNote
CDMO$17.8M-18.0%70.3%—
HA manufacturing$7.5M-19.0%29.7%—

Margins and costs

  • Gross margin 27% (prior 25%, change +2 pp)
  • Operating expenses $7.7M (-29.0% YoY)
  • One-offs in the quarter Restructuring recovery $2.9M; Loss on sale or disposal of assets $6.9M
  • Effective tax rate 0.1% (prior-year 3.3%)
  • Non-GAAP bridge Adds back interest expense, stock-based compensation, change in fair value of debt derivatives, reorganization costs, restructuring recovery, and loss on sale of assets to GAAP net loss.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$23.0M$17.2M$17.5M+5.8M
Liquidity$38.0M$38.8MN/A-0.8M
Revolving credit availability$15.0M$21.6MN/A-6.6M
Operating cash flows$9.5M$2.5M$6.5M+7.0M

Guidance

not stated in the 8-K

What drove it

  • Revenue story Revenue decreased 19.0% YoY to $25.3M, driven by declines in both CDMO (-18.0%) and HA manufacturing (-19.0%) segments.
  • EPS story Loss per share widened to $1.08 YoY, driven by a $30.1M increase in net loss, despite a $3.1M reduction in operating expenses.
  • One-off check Restructuring recovery $2.9M and loss on sale or disposal of assets $6.9M (net of portion classified as cost of sales).

The good

  • Free cash flow turned positive at $6.9M YoY
  • Operating expenses decreased 29.0% YoY

The bad

  • Revenue declined 19.0% YoY
  • Gross profit declined 12.0% YoY

The ugly

  • none

Open questions

  • The release references a proposed merger but does not disclose financial impact or updated guidance.
  • The company does not provide 2026 GAAP net loss guidance or a quantitative reconciliation of Adjusted EBITDA.
Full release

Lifecore Biomedical (LFCR) earnings release, November 4, 2026

Lifecore Biomedical, Inc. (LFCR) · Form 8-K, Item 2.02 · Filed · SEC filing

Lifecore Biomedical Reports Financial Results for the Third Quarter Ended

September 30, 2026, and Provides Corporate Update

-- Multiple New Business Wins Continue to Strengthen Growing Pipeline --

CHASKA, Minn., November 4, 2026

-- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the third quarter and nine months ended September 30, 2026.

CEO Commentary

“During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginning in 2027,” said Paul Josephs, president and chief executive officer of Lifecore. “In addition, early in the fourth quarter, we secured three new development-phase programs. These include one Phase 2 product with a top-20 global pharmaceutical company and two Phase 3 products with two biotech companies.”

Financial Snapshot

• Revenues for the third quarter of 2026 were $25.3 million, a decrease of $5.8 million, or

18.6% compared to $31.1 million for the prior year quarter ended September 30, 2025. Revenues for the nine months ended September 30, 2026, were $82.7 million, a decrease of $23.0 million, or 21.8% compared to $105.7 million for the nine months ended September 30, 2025.

• Gross profit for the quarter was $6.8 million, a decrease of $1.0 million compared to $7.8 million for the prior year quarter ended September 30, 2025. Gross profit for the nine months ended September 30, 2026, was $23.4 million, a decrease of $11.3 million compared to $34.7 million for the nine months ended September 30, 2025.

• Operating expenses for the third quarter were $7.7 million, a decrease of $3.1 million, or 28.9%, compared to $10.9 million for the prior year quarter ended September 30, 2025. Operating expenses for the nine months ended September 30, 2026, were $26.4 million, a decrease of $10.0 million, or 27.5%, compared to $36.4 million for the nine months ended September 30, 2025.

• Cash from operations was $9.5 million and free cash flow* was $6.9 million for the nine months ended September 30, 2026.

• Net loss for the third quarter of 2026 was $40.1 million or $1.08 loss per diluted share, as compared to net loss of $10.0 million or $0.29 loss per diluted share, for the prior year quarter ended September 30, 2025. Net loss for the nine months ended September 30, 2026, was $61.2 million or $1.70 loss per diluted share, as compared to net loss of $20.9 million or $0.64 loss per diluted share for the nine months ended September 30, 2025.

• Adjusted EBITDA* for the third quarter was $4.0 million, an increase of $1.0 million compared to $3.1 million for the prior year quarter ended September 30, 2025. Adjusted EBITDA* for the nine months ended September 30, 2026, was $13.6 million, a decrease of $7.4 million compared to $21.1 million for the nine months ended September 30, 2025.

• Ended the third quarter of 2026 with approximately $38.0 million in liquidity, including cash of

$23.0 million and revolving credit availability of $15.0 million.

* Adjusted EBITDA and free cash flow are non-GAAP financial measures and exclude certain items from net income or loss and operating cash flows, respectively, the nearest comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Please see “Non-GAAP Financial Information” below for more information, including definitions of Adjusted EBITDA and free cash flow and reconciliations to net loss and operating cash flows, respectively, for the periods noted in this press release.

Supplemental Financial Data

Supplemental Revenue and Gross Profit Data

Supplemental Operating Expense Data

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Non-GAAP Financial Information

In addition to providing financial measurements based on generally accepted accounting principles in the United States of America (GAAP), this press release contains non-GAAP financial information. Adjusted EBITDA and free cash flow are non-GAAP measures and exclude certain items from net income or loss and operating cash flows, respectively, which are the most directly comparable financial measures calculated in accordance with GAAP. See the section entitled “Non-GAAP Financial Reconciliations” below for the company’s definitions of Adjusted EBITDA and free cash flows and reconciliations to net income or loss and operating cash flows, respectively, for each period presented.... (truncated)nancial measures provide useful additional information to investors about trends in the company’s operations and are useful for period-over-period comparisons. Management uses Adjusted EBITDA and free cash flow, in addition to GAAP financial measures, to monitor trends in the company’s operations, understand and compare operating results, and monitor cash flows across accounting periods, for financial and operational decision making, for planning and forecasting purposes, and with respect to Adjusted EBITDA as a measure of performance for compensation decisions.

These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP financial measures may not be the same as similar measures provided by other companies due to the potential differences in methods of calculation and items being excluded/included. These non-GAAP financial measures should be read in conjunction with the company’s consolidated financial statements presented in accordance with GAAP.

Financial statements

Income Statement

Three months ended September 30, — Supplemental Revenue and Gross Profit Data (in thousands)

Three months ended September 30, – 2026Three months ended September 30, – 2025Change – AmountChange – %
Revenues:
CDMO17,77721,749-3,972-18.0%
HA manufacturing7,5459,360-1,815-19.0%
Total revenues25,32231,109-5,787-19.0%
Cost of sales18,49623,318-4,822-21.0%
Gross profit6,8267,791-965-12.0%
Gross profit percentage27252

Income Statement

Nine months ended September 30, — Supplemental Revenue and Gross Profit Data (in thousands)

Nine months ended September 30, – 2026Nine months ended September 30, – 2025Change – AmountChange – %
Revenues:
CDMO49,10469,382-20,278-29.0%
HA manufacturing33,57836,304-2,726-8.0%
Total revenues82,682105,686-23,004-22.0%
Cost of sales59,31970,981-11,662-16.0%
Gross profit23,36334,705-11,342-33.0%
Gross profit percentage28.332.8-4.5

Income Statement

Three months ended September 30, — Supplemental Operating Expense Data (in thousands)

Three months ended September 30, – 2026Three months ended September 30, – 2025Change – AmountChange – %
(dollars in thousands)
Research and development1,4211,963-542-28.0%
Selling, general and administrative6,2998,895-2,596-29.0%
Total operating expenses7,72010,858-3,138-29.0%

Income Statement

Nine months ended September 30, — Supplemental Operating Expense Data (in thousands)

Nine months ended September 30, – 2026Nine months ended September 30, – 2025Change – AmountChange – %
(dollars in thousands)
Research and development4,1756,014-1,839-31.0%
Selling, general and administrative22,18726,349-4,162-16.0%
Restructuring recovery-2,9372,937n/m
Loss on sale or disposal of assets, net of portion classified as cost of sales6,942-6,942n/m
Total operating expenses26,36236,368-10,006-28.0%

Income Statement

Three months ended September 30, — (unaudited) (in thousands, except share and per share amounts)

Three months ended September 30, – 2026Three months ended September 30, – 2025Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Revenues13,58619,29339,30257,314
Revenues, related party11,73611,81643,38048,372
Total revenues25,32231,10982,682105,686
Cost of sales18,49623,31859,31970,981
Gross profit6,8267,79123,36334,705
Research and development expenses1,4211,9634,1756,014
Selling, general, and administrative expenses6,2998,89522,18726,349
Restructuring recovery-2,937
Loss on sale or disposal of assets, net of portion classified as cost of sales6,942
Operating loss-894-3,067-2,999-1,663
Interest income23258504472
Interest expense-425-551-1,359-1,721
Interest expense, related party-7,675-5,833-21,840-16,031
Change in fair value of debt derivative liability, related party-31,270-375-35,628-1,991
Other (expense) income, net-1110219359
Loss before income taxes-40,033-9,658-61,103-20,575
Income tax expense-51-333-117-359
Net loss-40,084-9,991-61,220-20,934
Preferred stock dividends-941-874-2,772-2,573
Accretion of preferred stock to redemption value-48-94-144
Loss available to common stockholders-41,025-10,913-64,086-23,651
Loss per share, basic and diluted-1.08-0.29-1.7-0.64
Weighted average shares outstanding, basic and diluted37,845,47837,402,91237,633,81637,148,750

Income Statement

Three months ended September 30, (in thousands)

Three months ended September 30, – 2026Three months ended September 30, – 2025Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Net loss (GAAP)-40,084-9,991-61,220-20,934
Interest expense, net7,8686,32622,69517,280
Income tax expense51333117359
Depreciation2,4101,9817,2355,968
Stock-based compensation1,7152,3925,4986,404
Change in fair value of debt derivatives31,27037535,6281,991
Franchise tax526315283
Reorganization costs7201,5713,5095,104
Restructuring recovery-2,937
Loss on sale or disposal of assets7,738
Adjusted EBITDA4,0023,05013,61421,056

Balance Sheet

September 30, 2026 — (unaudited) (in thousands, except share and per share amounts)

September 30, 2026December 31, 2025
Cash and cash equivalents23,03517,469
Accounts receivable, net9,07713,233
Accounts receivable, related party11,99512,929
Contract assets10,2757,655
Inventory27,69529,085
Prepaid expenses and other current assets2,6041,921
Total current assets84,68182,292
Property, plant and equipment, net122,040127,304
Goodwill13,88113,881
Other assets7,7018,700
Total assets228,303232,177
Current liabilities:
Accounts payable8,5876,211
Accrued expenses and other current liabilities13,45317,362
Total current liabilities22,04023,573
Debt, net of current portion5,5355,694
Debt, net of current portion, related party154,452135,588
Debt derivative liability, related party62,19226,564

Cash Flow

Nine months ended September 30, — See “Non-GAAP Financial Information” above for further information regarding the company’s use of non-GAAP financial measures. (in thousands)

Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Operating cash flows (GAAP)9,45712,506
Less: capital expenditures-2,543-9,792
Free cash flow6,9142,714

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “aim,” “designed to,” “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our future financial and operating performance and strategy, including our belief that the newly signed programs will be additive to our high-value pipeline, and our expectation that each will contribute to our long-term revenue growth objectives starting in 2027, are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors as, among others, the timing and amount of future expenses, revenue, net income (loss), Adjusted EBITDA, cash flow and capital requirements, and timing and availability of and the need for additional financing; our ability to maintain or expand our relationships with our current customers, including the impact of changes in consumer demand for the products we manufacture for our customers; our ability to grow and diversify our business with new customers, including the potential loss of development customers if they do not receive required funding or regulatory approvals or for other reasons; our ability to comply with covenants under our credit agreements and to pay required interest and principal payments when due; our ability to fund or pay redemptions of shares of the outstanding Series A Convertible Preferred Stock in accordance with their terms; our ability to raise additional capital for ongoing needs, including through equity financing, debt financing, collaborations, strategic alliances or licensing arrangements; the impact of macroeconomic events or circumstances on our operations and financial performance, including inflation, tariffs, interest rates, social unrest and global instability; the performance of our third-party suppliers; pharmaceutical industry market forces that may impact our customers’ success and continued demand for the products we produce for those customers; our ability to recruit or retain key scientific, technical, business development, and management personnel and our executive officers; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice, or cGMP; the outcome and cost of existing and any new litigation or regulatory proceedings; and other risk factors set forth from time to time in the company’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Transition Report on Form 10-KT for the transition period ended December 31, 2025 (the “December 2025 10-KT”). In addition, forward looking statements in this press release may be impacted by risks and uncertainties relating to the Company’s previously announced proposed merger pursuant to an Agreement and Plan of Merger dated September 27, 2026 among the Company, Lifecore Inc. and Hazel Merger Sub, Inc. These risks and uncertainties include, but are not limited to: (1) the proposed transaction may not be completed in a timely manner or at all, which may adversely affect Lifecore’s business and the price of its common stock; (2) the occurrence of any fact, event, change, development or circumstance that could give rise to the termination of the transaction agreement, including in circumstances requiring Lifecore to pay a termination fee; (3) the proposed transaction and its announcement could have an adverse effect on the ability of Lifecore to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders and other business relationships and on its operating results and business generally; (4) risks related to the diversion of management’s attention from Lifecore’s ongoing business operations; (5) unexpected costs, charges or expenses resulting from the proposed transaction; (6) potential litigation relating to the proposed transaction that could be instituted against the parties to the transaction agreement or their respective directors, managers or officers, including the effects of any outcomes related thereto; (7) certain restrictions during the pendency of the proposed transaction that may impact Lifecore’s ability to make changes in its business, pursue certain business opportunities or strategic transactions; (8) uncertainties pertaining to other business effects, including the effects of industry, market, economic, political or regulatory conditions, future interest rates and changes in tax and other laws, regulations, rates and policies, and (9) the effect of the announcement or pendency of the transaction on Lifecore’s business, operating results and relationships with collaborators, vendors, competitors and others. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the SEC, including the risk factors contained in the December 2025 10-KT and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

Forward-looking statements represent management’s current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

Lifecore Biomedical, Inc. Contact Information:

Stephanie Diaz (Investors)

Vida Strategic Partners

415-675-7401 sdiaz@vidasp.com

Jennifer Arcure (Media)

Vida Strategic Partners

917-603-0681 jarcure@vidasp.com

Ryan D. Lake (CFO)

Lifecore Biomedical

952-368-6244 ryan.lake@lifecore.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Lifecore Biomedical earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.